PanGen Biotech, Inc. engages in the production and sales of biopharmaceuticals. Its products include biosimilar erythropoietin (EPO), recombinant Factor VIII, biosimilar Aflibercept, recombinant anti-SFTSV Ab, and biosimilar G-CSF. The company was founded on January 29, 2010 and is headquartered in Suwon-si, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company